- Meeting abstract
- Open Access
308 MR guidance and monitoring of intramyocardial delivery of VEGF Gene in coronary artery occlusion in canine model
© Saeed et al; licensee BioMed Central Ltd. 2008
- Published: 22 October 2008
- Coronary Artery Occlusion
- Therapeutic Angiogenesis
- VEGF Gene
- Increase Ejection Fraction
- Endovascular Catheter
Ischemic cardiomyopathy resulting from LV remodeling and conversion of myocytes to scar tissue is the eventual scenario in severe coronary disease. A candidate treatment for this condition is therapeutic angiogenesis. A percutaneous transendocardial approach to therapeutic angiogenesis in ischemic myocardium aims to: 1) achieve locally effective concentration of therapy; 2) minimize side-effects associated with systemic distribution; 3) minimize the effect of blood enzymes on genes and 4) eliminate open-chest surgery and extended hospitalization.
To: 1) explore the effectiveness of MR-fluoroscopy for targeted delivery of genes in occlusive infarction; and 2) evaluate VEGF gene effect on MR measurements of perfusion, infarction size and LV function.
MR-guided transendocardial delivery of genes into occlusive infarction is an effective technique for revascularization. This new delivery approach resulted in improved global LV function and prevented LV remodeling that otherwise was noted to occur in control animals at 7–8 weeks after occlusion. The effectiveness of this approach most likely stems from the effect of VEGF in promoting new blood vessels in the target.
This article is published under license to BioMed Central Ltd.